{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T03:27:36Z","timestamp":1795058856157,"version":"4.10.2"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004012","name":"Jane ja Aatos Erkon S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","award":["4705796"],"award-info":[{"award-number":["4705796"]}],"id":[{"id":"10.13039\/501100004012","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-68466-5","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T14:23:59Z","timestamp":1769610239000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Leveraging glucan-induced trained immunity for the epigenetic and metabolic rewiring of macrophages to enhance colorectal cancer vaccine response"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4678-7382","authenticated-orcid":false,"given":"Firas","family":"Hamdan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6207-4433","authenticated-orcid":false,"given":"Sara","family":"Gandolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"D\u2019Alessio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4265-5411","authenticated-orcid":false,"given":"Yvonne","family":"Giannoula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Kolikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7166-3018","authenticated-orcid":false,"given":"Manlio","family":"Fusciello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6665-296X","authenticated-orcid":false,"given":"Elisa","family":"Zaghen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Napolano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozan","family":"Izci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Bottega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6577-2691","authenticated-orcid":false,"given":"Jacopo","family":"Chiaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0068-6850","authenticated-orcid":false,"given":"Kirsi-Marja","family":"Alanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Antignani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6094-9838","authenticated-orcid":false,"given":"Michaela","family":"Feodoroff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virpi","family":"Stigzelius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milda","family":"Sakalauskaite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janita","family":"Sandberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8999-6040","authenticated-orcid":false,"given":"Anni I.","family":"Nieminen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Zambrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ove","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0816-8241","authenticated-orcid":false,"given":"Satu","family":"Mustjoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni T.","family":"Sepp\u00e4l\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikaela","family":"Gr\u00f6nholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4901-3796","authenticated-orcid":false,"given":"Vincenzo","family":"Cerullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"key":"68466_CR1","first-page":"7","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2021. CA Cancer J. Clin. 71, 7\u201333 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"68466_CR2","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1136\/gutjnl-2022-327736","volume":"72","author":"E Morgan","year":"2023","unstructured":"Morgan, E. et al. Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut 72, 338\u2013344 (2023).","journal-title":"Gut"},{"key":"68466_CR3","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1470-2045(24)00600-4","volume":"26","author":"H Sung","year":"2025","unstructured":"Sung, H. et al. Colorectal cancer incidence trends in younger versus older adults: an analysis of population-based cancer registry data. Lancet Oncol. 26, 51\u201363 (2025).","journal-title":"Lancet Oncol."},{"key":"68466_CR4","doi-asserted-by":"crossref","first-page":"102370","DOI":"10.1016\/j.canep.2023.102370","volume":"85","author":"AB Mariotto","year":"2023","unstructured":"Mariotto, A. B., Thompson, T. D., Johnson, C., Wu, X. C. & Pollack, L. A. Breast and colorectal cancer recurrence-free survival estimates in the US: modeling versus active data collection. Cancer Epidemiol. 85, 102370 (2023).","journal-title":"Cancer Epidemiol."},{"key":"68466_CR5","volume":"15","author":"S Yan","year":"2024","unstructured":"Yan, S. et al. Immune checkpoint inhibitors in colorectal cancer: limitation and challenges. Front Immunol. 15, 1403533 (2024).","journal-title":"Front Immunol."},{"key":"68466_CR6","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.ejca.2024.114033","volume":"202","author":"M Moreau","year":"2024","unstructured":"Moreau, M. et al. A multicenter study evaluating efficacy of immune checkpoint inhibitors in advanced non-colorectal digestive cancers with microsatellite instability. Eur. J. Cancer 202, 959\u20138049 (2024).","journal-title":"Eur. J. Cancer"},{"key":"68466_CR7","doi-asserted-by":"publisher","unstructured":"Andr\u00e9, T., Cohen, R. & Salem, M. E. Immune checkpoint blockade therapy in patients with colorectal cancer harboring microsatellite instability\/mismatch repair deficiency in 2022. American Society of Clinical Oncology Educational Book 233\u2013241 https:\/\/doi.org\/10.1200\/EDBK_349557 (2022).","DOI":"10.1200\/EDBK_349557"},{"key":"68466_CR8","doi-asserted-by":"crossref","unstructured":"Yamaguchi, K. et al. Efficacy of pembrolizumab in microsatellite-stable, tumor mutational burden-high metastatic colorectal cancer: genomic signatures and clinical outcomes. ESMO Open 10, 104108 (2025).","DOI":"10.1016\/j.esmoop.2024.104108"},{"key":"68466_CR9","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1126\/science.1129139","volume":"313","author":"J Galon","year":"2006","unstructured":"Galon, J. et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960\u20131964 (2006).","journal-title":"Science"},{"key":"68466_CR10","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le, D. T. et al. Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357, 409 (2017).","journal-title":"Science"},{"key":"68466_CR11","volume":"12","author":"S Hazama","year":"2014","unstructured":"Hazama, S. et al. A phase \u0399I study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study). J. Transl. Med. 12, 108 (2014).","journal-title":"J. Transl. Med"},{"key":"68466_CR12","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.clim.2016.03.015","volume":"166\u2013167","author":"M Murahashi","year":"2016","unstructured":"Murahashi, M. et al. Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors. Clin. Immunol. 166\u2013167, 48\u201358 (2016).","journal-title":"Clin. Immunol."},{"key":"68466_CR13","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1200\/JCO.2000.18.1.148","volume":"18","author":"JE Harris","year":"2000","unstructured":"Harris, J. E. et al. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group study E5283. J. Clin. Oncol. 18, 148\u2013157 (2000).","journal-title":"J. Clin. Oncol."},{"key":"68466_CR14","doi-asserted-by":"crossref","first-page":"7726","DOI":"10.1158\/1078-0432.CCR-09-1537","volume":"15","author":"HC Toh","year":"2009","unstructured":"Toh, H. C. et al. Clinical benefit of allogeneic melanoma cell lysate-pulsed autologous dendritic cell vaccine in mage-positive colorectal cancer patients. Clin. Cancer Res. 15, 7726\u20137736 (2009).","journal-title":"Clin. Cancer Res"},{"key":"68466_CR15","doi-asserted-by":"crossref","unstructured":"Saito, T. et al. Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers. Nat. Med. 22, 679\u2013684 (2016).","DOI":"10.1038\/nm.4086"},{"key":"68466_CR16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1479-5876-4-52","volume":"4","author":"C Loddenkemper","year":"2006","unstructured":"Loddenkemper, C. et al. In situ analysis of FOXP3+ regulatory T cells in human colorectal cancer. J. Transl. Med. 4, 1\u20138 (2006).","journal-title":"J. Transl. Med"},{"key":"68466_CR17","first-page":"3311","volume":"119","author":"A Bonertz","year":"2009","unstructured":"Bonertz, A. et al. Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J. Clin. Invest. 119, 3311 (2009).","journal-title":"J. Clin. Invest"},{"key":"68466_CR18","doi-asserted-by":"crossref","first-page":"e57114","DOI":"10.1371\/journal.pone.0057114","volume":"8","author":"B Zhang","year":"2013","unstructured":"Zhang, B. et al. Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma. PLoS One 8, e57114 (2013).","journal-title":"PLoS One"},{"key":"68466_CR19","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.semcancer.2013.02.007","volume":"23","author":"S Brandau","year":"2013","unstructured":"Brandau, S., Moses, K. & Lang, S. The kinship of neutrophils and granulocytic myeloid-derived suppressor cells in cancer: cousins, siblings or twins?. Semin Cancer Biol. 23, 171\u2013182 (2013).","journal-title":"Semin Cancer Biol."},{"key":"68466_CR20","doi-asserted-by":"crossref","first-page":"e1494113","DOI":"10.1080\/2162402X.2018.1494113","volume":"7","author":"PF Wang","year":"2018","unstructured":"Wang, P. F. et al. Prognostic role of pretreatment circulating MDSCs in patients with solid malignancies: a meta-analysis of 40 studies. Oncoimmunology 7, e1494113 (2018).","journal-title":"Oncoimmunology"},{"key":"68466_CR21","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s00384-020-03593-z","volume":"35","author":"J Li","year":"2020","unstructured":"Li, J. et al. Tumor-associated macrophage infiltration and prognosis in colorectal cancer: systematic review and meta-analysis. Int J. Colorectal Dis. 35, 1203\u20131210 (2020).","journal-title":"Int J. Colorectal Dis."},{"key":"68466_CR22","doi-asserted-by":"crossref","DOI":"10.1186\/1479-5876-8-13","volume":"8","author":"Q Zhou","year":"2010","unstructured":"Zhou, Q. et al. The density of macrophages in the invasive front is inversely correlated to liver metastasis in colon cancer. J. Transl. Med. 8, 13 (2010).","journal-title":"J. Transl. Med"},{"key":"68466_CR23","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1158\/1078-0432.CCR-06-2073","volume":"13","author":"J Forssell","year":"2007","unstructured":"Forssell, J. et al. High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Clin. Cancer Res. 13, 1472\u20131479 (2007).","journal-title":"Clin. Cancer Res"},{"key":"68466_CR24","volume":"5","author":"VH Koelzer","year":"2015","unstructured":"Koelzer, V. H. et al. Phenotyping of tumor-associated macrophages in colorectal cancer: Impact on single cell invasion (tumor budding) and clinicopathological outcome. Oncoimmunology 5, e1106677 (2015).","journal-title":"Oncoimmunology"},{"key":"68466_CR25","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s10735-012-9435-x","volume":"43","author":"Q Zhu","year":"2012","unstructured":"Zhu, Q., Han, X., Peng, J., Qin, H. & Wang, Y. The role of CXC chemokines and their receptors in the progression and treatment of tumors. J. Mol. Histol. 43, 699\u2013713 (2012).","journal-title":"J. Mol. Histol."},{"key":"68466_CR26","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","volume":"15","author":"DE Johnson","year":"2018","unstructured":"Johnson, D. E., O\u2019Keefe, R. A. & Grandis, J. R. Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer. Nat. Rev. Clin. Oncol. 15, 234 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"68466_CR27","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.3390\/cancers12123850","volume":"12","author":"Y Zhang","year":"2020","unstructured":"Zhang, Y., Rajput, A., Jin, N. & Wang, J. Mechanisms of immunosuppression in colorectal cancer. Cancers (Basel) 12, 3850 (2020).","journal-title":"Cancers (Basel)"},{"key":"68466_CR28","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/s41577-020-0285-6","volume":"20","author":"MG Netea","year":"2020","unstructured":"Netea, M. G. et al. Defining trained immunity and its role in health and disease. Nat. Rev. Immunol. 20, 375\u2013388 (2020). 2020 20:6.","journal-title":"Nat. Rev. Immunol."},{"key":"68466_CR29","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1093\/infdis\/jiz692","volume":"222","author":"E Ciarlo","year":"2019","unstructured":"Ciarlo, E. et al. Trained immunity confers broad-spectrum protection against bacterial infections. J. Infect. Dis. 222, 1869 (2019).","journal-title":"J. Infect. Dis."},{"key":"68466_CR30","doi-asserted-by":"crossref","unstructured":"Moorlag, S. J. C. F. M. et al. \u03b2-Glucan induces protective trained immunity against Mycobacterium tuberculosis infection: a key role for IL-1. Cell Rep. 31, 107634 (2020).","DOI":"10.1016\/j.celrep.2020.107634"},{"key":"68466_CR31","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1093\/infdis\/jiz692","volume":"222","author":"E Ciarlo","year":"2020","unstructured":"Ciarlo, E. et al. Trained immunity confers broad-spectrum protection against bacterial infections. J. Infect. Dis. 222, 1869\u20131881 (2020).","journal-title":"J. Infect. Dis."},{"key":"68466_CR32","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41590-024-02041-2","volume":"26","author":"N Khan","year":"2025","unstructured":"Khan, N. et al. \u03b2-Glucan reprograms neutrophils to promote disease tolerance against influenza A virus. Nat. Immunol. 26, 174\u2013187 (2025).","journal-title":"Nat. Immunol."},{"key":"68466_CR33","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3181\/00379727-152-39327","volume":"152","author":"SE Starr","year":"1976","unstructured":"Starr, S. E., Visintine, A. M., Tomeh, M. O. & Nahmias, A. J. Effects of immunostimulants on resistance of newborn mice to herpes simplex type 2 infection. Proc. Soc. Exp. Biol. Med. 152, 57\u201360 (1976).","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"68466_CR34","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1128\/iai.20.1.312-314.1978","volume":"20","author":"T Suenaga","year":"1978","unstructured":"Suenaga, T., Okuyama, T., Yoshida, I. & Azuma, M. Effect of Mycobacterium tuberculosis BCG infection on the resistance of mice to ectromelia virus infection: participation of interferon in enhanced resistance. Infect. Immun. 20, 312\u2013314 (1978).","journal-title":"Infect. Immun."},{"key":"68466_CR35","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/infdis\/136.2.171","volume":"136","author":"JC Spencer","year":"1977","unstructured":"Spencer, J. C., Ganguly, R. & Waldman, R. H. Nonspecific protection of mice against influenza virus infection by local or systemic immunization with bacille calmette-guerin. J. Infect. Dis. 136, 171\u2013175 (1977).","journal-title":"J. Infect. Dis."},{"key":"68466_CR36","first-page":"173","volume":"127","author":"F Floc\u2019h","year":"1976","unstructured":"Floc\u2019h, F. & Werner, G. H. Increased resistance to virus infections of mice inoculated with BCG (Bacillus calmette-gu\u00e9rin). Ann. Immunol. (Paris) 127, 173\u2013186 (1976).","journal-title":"Ann. Immunol. (Paris)"},{"key":"68466_CR37","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1248\/bpb.b23-00802","volume":"47","author":"Y Masuda","year":"2024","unstructured":"Masuda, Y., Yamashita, S., Nakayama, Y., Shimizu, R. & Konishi, M. Maitake beta-glucan enhances the therapeutic effect of trastuzumab via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Biol. Pharm. Bull. 47, 840\u2013847 (2024).","journal-title":"Biol. Pharm. Bull."},{"key":"68466_CR38","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.cell.2020.09.058","volume":"183","author":"L Kalafati","year":"2020","unstructured":"Kalafati, L. et al. Innate immune training of granulopoiesis promotes anti-tumor activity. Cell 183, 771\u2013785.e12 (2020).","journal-title":"Cell"},{"key":"68466_CR39","doi-asserted-by":"crossref","unstructured":"Wattenberg, M. M. et al. Cancer immunotherapy via synergistic coactivation of myeloid receptors CD40 and Dectin-1. Sci. Immunol. 8, eadj5097 (2023).","DOI":"10.1126\/sciimmunol.adj5097"},{"key":"68466_CR40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-022-28407-4","volume":"13","author":"AE Geller","year":"2022","unstructured":"Geller, A. E. et al. The induction of peripheral trained immunity in the pancreas incites anti-tumor activity to control pancreatic cancer progression. Nat. Commun. 13, 1\u201320 (2022).","journal-title":"Nat. Commun."},{"key":"68466_CR41","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.826164","volume":"13","author":"S Feola","year":"2022","unstructured":"Feola, S. et al. Peptides-Coated Oncolytic Vaccines for Cancer Personalized Medicine. Front Immunol. 13, 826164 (2022).","journal-title":"Front Immunol."},{"key":"68466_CR42","doi-asserted-by":"crossref","unstructured":"Capasso, C. et al. Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma. Oncoimmunology 5, e1105429 (2015).","DOI":"10.1080\/2162402X.2015.1105429"},{"key":"68466_CR43","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1038\/s12276-020-00486-7","volume":"52","author":"HG Lee","year":"2020","unstructured":"Lee, H. G., Cho, M. Z. & Choi, J. M. Bystander CD4+ T cells: crossroads between innate and adaptive immunity. Exp. Mol. Med. 52, 1255\u20131263 (2020).","journal-title":"Exp. Mol. Med."},{"key":"68466_CR44","doi-asserted-by":"crossref","unstructured":"Feola, S. et al. A novel immunopeptidomic-based pipeline for the generation of personalized oncolytic cancer vaccines. Elife 11, e71156 (2022).","DOI":"10.7554\/eLife.71156"},{"key":"68466_CR45","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1016\/j.immuni.2023.11.008","volume":"56","author":"O Dufva","year":"2023","unstructured":"Dufva, O. et al. Single-cell functional genomics reveals determinants of sensitivity and resistance to natural killer cells in blood cancers. Immunity 56, 2816\u20132835.e13 (2023).","journal-title":"Immunity"},{"key":"68466_CR46","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41591-018-0085-8","volume":"24","author":"KC Barry","year":"2018","unstructured":"Barry, K. C. et al. A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments. Nat. Med 24, 1178\u20131191 (2018).","journal-title":"Nat. Med"},{"key":"68466_CR47","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.cell.2018.01.004","volume":"172","author":"JP B\u00f6ttcher","year":"2018","unstructured":"B\u00f6ttcher, J. P. et al. NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. Cell 172, 1022\u20131037.e14 (2018).","journal-title":"Cell"},{"key":"68466_CR48","doi-asserted-by":"crossref","unstructured":"Ray, A. et al. Targeting CD206+ macrophages disrupts the establishment of a key antitumor immune axis. J. Exp. Med. 222, e20240957 (2025).","DOI":"10.1084\/jem.20240957"},{"key":"68466_CR49","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.ccell.2014.11.010","volume":"26","author":"ML Broz","year":"2014","unstructured":"Broz, M. L. et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell 26, 938 (2014).","journal-title":"Cancer Cell"},{"key":"68466_CR50","doi-asserted-by":"crossref","first-page":"7465","DOI":"10.1158\/0008-5472.CAN-10-1439","volume":"70","author":"AL Doedens","year":"2010","unstructured":"Doedens, A. L. et al. Macrophage expression of hypoxia-inducible factor-1\u03b1 suppresses T-cell function and promotes tumor progression. Cancer Res. 70, 7465\u20137475 (2010).","journal-title":"Cancer Res"},{"key":"68466_CR51","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1158\/0008-5472.CAN-12-2731","volume":"73","author":"JB Mitchem","year":"2013","unstructured":"Mitchem, J. B. et al. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res. 73, 1128\u20131141 (2013).","journal-title":"Cancer Res"},{"key":"68466_CR52","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1016\/j.immuni.2022.10.002","volume":"55","author":"BG Nixon","year":"2022","unstructured":"Nixon, B. G. et al. Tumor-associated macrophages expressing the transcription factor IRF8 promote T cell exhaustion in cancer. Immunity 55, 2044\u20132058.e5 (2022).","journal-title":"Immunity"},{"key":"68466_CR53","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/s41590-023-01475-4","volume":"24","author":"MD Park","year":"2023","unstructured":"Park, M. D. et al. TREM2 macrophages drive NK cell paucity and dysfunction in lung cancer. Nat. Immunol. 24, 792\u2013801 (2023).","journal-title":"Nat. Immunol."},{"key":"68466_CR54","doi-asserted-by":"crossref","first-page":"E4041","DOI":"10.1073\/pnas.1720948115","volume":"115","author":"E Peranzoni","year":"2018","unstructured":"Peranzoni, E. et al. Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti\u2013PD-1 treatment. Proc. Natl. Acad. Sci. USA 115, E4041\u2013E4050 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"68466_CR55","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.ccell.2014.09.006","volume":"26","author":"B Ruffell","year":"2014","unstructured":"Ruffell, B. et al. Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell 26, 623\u2013637 (2014).","journal-title":"Cancer Cell"},{"key":"68466_CR56","doi-asserted-by":"crossref","first-page":"724883","DOI":"10.3389\/fimmu.2021.724883","volume":"12","author":"B Subtil","year":"2021","unstructured":"Subtil, B., Cambi, A., Tauriello, D. V. F. & de Vries, I. J. M. The therapeutic potential of tackling tumor-induced dendritic cell dysfunction in colorectal cancer. Front Immunol. 12, 724883 (2021).","journal-title":"Front Immunol."},{"key":"68466_CR57","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.4049\/jimmunol.1100403","volume":"187","author":"B Zhu","year":"2011","unstructured":"Zhu, B. et al. Plasticity of Ly-6Chi myeloid cells in T cell regulation. J. Immunol. 187, 2418 (2011).","journal-title":"J. Immunol."},{"key":"68466_CR58","first-page":"E3186","volume":"109","author":"P Ramachandran","year":"2012","unstructured":"Ramachandran, P. et al. Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis. Proc. Natl. Acad. Sci. USA 109, E3186\u2013E3195 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"68466_CR59","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","volume":"14","author":"A Mantovani","year":"2017","unstructured":"Mantovani, A., Marchesi, F., Malesci, A., Laghi, L. & Allavena, P. Tumour-associated macrophages as treatment targets in oncology. Nat. Rev. Clin. Oncol. 14, 399\u2013416 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"68466_CR60","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00281-024-01015-8","volume":"46","author":"AV Ferreira","year":"2024","unstructured":"Ferreira, A. V., Dom\u00ednguez-Andr\u00e9s, J., Merlo Pich, L. M., Joosten, L. A. B. & Netea, M. G. Metabolic regulation in the induction of trained immunity. Semin Immunopathol. 46, 7 (2024).","journal-title":"Semin Immunopathol."},{"key":"68466_CR61","doi-asserted-by":"crossref","first-page":"1176956","DOI":"10.3389\/fimmu.2023.1176956","volume":"14","author":"Z Peng","year":"2023","unstructured":"Peng, Z. & Saito, S. Creatine supplementation enhances anti-tumor immunity by promoting adenosine triphosphate production in macrophages. Front Immunol. 14, 1176956 (2023).","journal-title":"Front Immunol."},{"key":"68466_CR62","doi-asserted-by":"crossref","first-page":"2291857","DOI":"10.1080\/21645515.2023.2291857","volume":"19","author":"A Bhagat","year":"2023","unstructured":"Bhagat, A., Lyerly, H. K., Morse, M. A. & Hartman, Z. C. CEA vaccines. Hum. Vaccin Immunother. 19, 2291857 (2023).","journal-title":"Hum. Vaccin Immunother."},{"key":"68466_CR63","doi-asserted-by":"crossref","unstructured":"Evers, M. et al. Novel chimerized IgA CD20 antibodies: Improving neutrophil activation against CD20-positive malignancies. MAbs 12, 1795505 (2020).","DOI":"10.1080\/19420862.2020.1795505"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68466-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68466-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68466-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T16:16:30Z","timestamp":1771344990000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68466-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["68466"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-68466-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]},"assertion":[{"value":"16 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"V.C. is co-founder and shareholder of Valo Therapeutics LTD. H.C. and L.K. are stakeholders of Valo Therapeutics LTD. Toni T. Sepp\u00e4l\u00e4 reports consultation fees from Mehil\u00e4inen, Nouscom, Orion Pharma, Amgen, and Tillots Pharma, and a position in the Clinical Advisory Board and as a minor shareholder of Lynsight Ltd. S.M. has received honoraria and research funding from Novartis, Pfizer, and Bristol-Myers Squibb and honoraria from Dren-Bio (not related to this study). V.S. is an employee and shareholder of AstraZeneca. All other named authors declare that they have no competing interests, financial or otherwise.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1757"}}